Abstract 3797
Background
To reveal candidate signaling pathways for targeted therapy in esophageal cancer (EC), and esophageal adenocarcinoma (EAC) in particular, we investigated key signal transduction pathways in material available in clinical routine, before and after neoadjuvant chemoradiation (nCRT), and for primary tumor and recurrent disease.
Methods
Paraffin-embedded material from three cohorts was used; (i) resectable EC; patients treated with an esophagectomy or receiving nCRT prior to resection, including cases with an available pre-nCRT biopsy of the primary tumor and corresponding resection; (ii) recurrent EC; patients of whom a resection and metachronous recurrence could be obtained. In addition, to explore the possibility to use patient-derived-xenografts (PDX) as a model to identify novel therapies, (iii) PDX of matched patient material was analyzed. Digitally annotated tumor areas ≥2 mm2 were transferred to a consecutive hematoxylin-stained slide and scraped for RNA extraction. Subsequently, a panel of qPCRs was performed, to infer signal transduction activity of the AR-, ER-, PI3K- (inverse of FOXO), HH-,TGF-β- and Wnt pathway.
Results
In pre-treatment EAC biopsies (i), high PI3K- and low TGF-β-pathway activity were correlated with poor pathological response. During treatment, a significant increase in PI3K- and decrease in TGF-β activity was observed in EAC poor nCRT responders compared to good responders (p = 0.003 and p = 0.042, respectively). Patients with a post-nCRT poor responder profile (high PI3K/ low TGF-β pathway activity) showed inferior disease free survival (median 17 vs. 97 months p = 0.055). Moreover, in nCRT treated patients, higher PI3K and lower TGF-β activities were seen in metachronous recurrences compared to resected tumors (ii) (p = 0.001 and p = 0.007, respectively). Pathway activity profiles were conserved between PDX and primary patient material (iii).
Conclusions
Loss of tumor-suppressive TGF-β and concurrent high PI3K pathway activity are associated with poor response to nCRT in EAC. This poor-responder profile is preserved in recurrences of nCRT pre-treated patients and PDX models, providing a valuable tool to experimentally test targeting candidate signal pathways such as PI3K.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Philips Research.
Funding
Philips Research.
Disclosure
L. Holtzer: Full / Part-time employment: Philips. M. Stoffels: Research grant / Funding (self), Full / Part-time employment: Philips. H. van Ooijen: Licensing / Royalties, Full / Part-time employment: Philips. A.G.C. van Brussel: Research grant / Funding (self), Licensing / Royalties, Full / Part-time employment: Philips. E.M.G. Aussems-Custers: Research grant / Funding (self), Licensing / Royalties, Full / Part-time employment: Philips. A. van de Stolpe: Licensing / Royalties, Full / Part-time employment: Philips. M.F. Bijlsma: Research grant / Funding (self): Celgene; Advisory / Consultancy: Servier. H.W.M. van Laarhoven: Advisory / Consultancy, Research grant / Funding (self): Celgene; Advisory / Consultancy, Research grant / Funding (self): BMS; Advisory / Consultancy, Research grant / Funding (self): Nordic; Advisory / Consultancy, Research grant / Funding (self): Lilly; Research grant / Funding (self): Merck Serono; Research grant / Funding (self): Bayer; Research grant / Funding (self): MSD; Research grant / Funding (self): Philips; Research grant / Funding (self): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
3266 - Morphology of tumor-associated macrophages dictates the prognosis of patients with colorectal liver metastases.
Presenter: Matteo Donadon
Session: Poster Display session 2
Resources:
Abstract
1694 - Pembrolizumab (pembro) Plus mFOLFOX or FOLFIRI in Patients With Metastatic Colorectal Cancer (mCRC): KEYNOTE-651 Cohorts B and D
Presenter: Richard Kim
Session: Poster Display session 2
Resources:
Abstract
908 - Romidepsin (FK228) Regulates the Expression of the Immune Checkpoint Ligand PD-L1 and Exerts Synergistic Anti-Tumor Activity with an Anti-PD-1 Antibody in Colon Cancer
Presenter: Hui Li
Session: Poster Display session 2
Resources:
Abstract
3127 - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.
Presenter: Zafeiris Zafeiriou
Session: Poster Display session 2
Resources:
Abstract
5416 - The SAFFO study: Sex-related prognostic role And cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
Presenter: Camilla Lisanti
Session: Poster Display session 2
Resources:
Abstract
2518 - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase
Presenter: Marwan Fakih
Session: Poster Display session 2
Resources:
Abstract
4000 - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Presenter: Niels Halama
Session: Poster Display session 2
Resources:
Abstract
2223 - Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer
Presenter: Wataru Okamoto
Session: Poster Display session 2
Resources:
Abstract
2569 - Phase II trial of Trametinib (T) and Panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
Presenter: Kanan Alshammari
Session: Poster Display session 2
Resources:
Abstract
5402 - Microsatellite instability and immunogenicity in colorectal cancer – do resident memory Tcells (Trm) play a role in colorectal cancer
Presenter: Wei Toh
Session: Poster Display session 2
Resources:
Abstract